M&A Deal Summary

WCG Acquires ProPhase

On May 9, 2017, WCG acquired test/measurement equipment company ProPhase

Acquisition Highlights
  • This is WCG’s 1st transaction in the Test/Measurement Equipment sector.
  • This is WCG’s 6th transaction in the United States.
  • This is WCG’s 1st transaction in New York.

M&A Deal Summary
Date 2017-05-09
Target ProPhase
Sector Test/Measurement Equipment
Buyer(s) WCG
Deal Type Add-on Acquisition

Target

ProPhase

New York, New York, United States
ProPhase is a global provider of measurement-related specialty solutions in clinical trials. For over a decade, ProPhase has focused on applying innovation to optimize the selection, use, and analysis of behavioral endpoints to mitigate trial risk and maximize the likelihood of study success. ProPhase specializes in the development of new outcome measures, calibration of real world outcomes, placebo response mitigation, and prediction of treatment adherence. These approaches have led to successful trials in indications across the CNS spectrum, as well as multiple rare and orphan diseases.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

WCG

Princeton, New Jersey, United States
Category Company
Founded 2012
Sector Information Services
DESCRIPTION

WCG is a provider of regulatory and ethical review services for human research. The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. WCG delivers transformational solutions that stimulate growth, foster compliance and maximize efficiency for those who perform clinical trials. WCG was founded in 2012 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 6 of 18
Sector (Test/Measurement Equipment) 1 of 1
Type (Add-on Acquisition) 5 of 17
State (New York) 1 of 1
Country (United States) 6 of 18
Year (2017) 3 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-09 MedAvante

Hamilton, New Jersey, United States

MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in global clinical trials. With VirgilÔ, its electronic clinical outcome assessment (eCOA) platform, clinical research sponsors are able to maximize outcome data quality and increase operational efficiency for clinical trials across multiple therapeutic areas. MedAvante built the first electronic source (eSource) data platform and has conducted more than 687,000 assessments of 56,000 clinical trial subjects across 233,000 study visits. MedAvante’s eSource data has been accepted by both the Food and Drug Administration and the European Medicines Agency in successful regulatory submissions.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-02 Patient Genesis

Fairfield, New Jersey, United States

Patient Genesis LLC (ConsentNow) is a developer of software which enables healthcare, pharmaceutical, and medical device companies to share important information with patients during the informed consent process in a format that is both easy-to-use and easy-to-understand. The technology employs custom video and animation segments to educate patients and online knowledge assessment questions to determine their level of understanding.

Buy -
Mergr

Product

Company

Legal